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Figures an tables: 
This paper includes three tables and three figures.  
 
Highlights: 
- T2DM patients with increased VAT volume are at risk for premature atherosclerosis.  
- VAT volume is positively associated with arterial inflammation in early T2DM. 
- Premature atherosclerosis was imaged with FDG and quantified as meanTBR. 
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Background and aims: Type 2 diabetes mellitus (T2DM) is commonly associated with abdominal 
obesity, predominantly with high visceral adipose tissue (VAT), and is accompanied by 
premature atherosclerosis. However, the association between VAT and subcutaneous adipose 
tissue (SAT) with premature atherosclerosis and (i.e. arterial) inflammation is incompletely 
understood. To provide more insight in this association we investigated the association between 
arterial 18F-fluordeoxyglucose (FDG) positron emission tomography (PET) uptake as a measure 
of arterial inflammation with metabolic syndrome (MetS) markers in early T2DM patients.    
Methods: Forty-four patients with early T2DM, without glucose lowering medication, were 
studied (median age 63 [IQR 54-66] years, median BMI 30.4 [IQR 27.5-35.8]). Arterial 
inflammation was quantified using glucose corrected maximum standardized uptake value 
(SUVmax) FDG of the aorta, carotid, iliac, and femoral arteries, and corrected for background 
activity (blood pool) as target-to-background ratio (meanTBR). VAT and SAT volumes (cm
3) were 
automatically segmented using computed tomography (CT) between levels L1-L5. Non-alcoholic 
fatty liver disease (NAFLD) was assessed by liver function test and CT.  
Results: VAT volume, but not SAT volume, correlated with meanTBR (r=0.325, p=0.031). Linear 
regression models showed a significant association, even after sequential adjustment for 
potentially influencing MetS components. Interaction term VAT volume * sex and additional 
components including HbA1c, insulin resistance, liver functionNAFLD, adiponectin, leptin, and C-




Conclusions: CT-assessed VAT volume is positively associated with FDG-PET assessed arterial 
inflammation, independently of factors thought to potentially mediate these effects. These 







Obesity is associated with an increased risk of developing type 2 diabetes mellitus 
(T2DM) and accelerates development of premature cardiovascular disease (CVD) (1). Although 
T2DM is associated with a strongly increased CVD risk, the process of irreversible subclinical 
vascular damage already starts during the pre-diabetes stage (2). This suggests that 
hyperglycaemia alone does not fully explain this risk suggests that and other factors are likely to 
be involved.  
Abdominal adipose tissue can be divided into visceral adipose tissue (VAT) and 
subcutaneous adipose tissue (SAT). Both are key contributors to abdominal obesity but their 
associated atherosclerotic risk profiles differ significantly (3,4). VAT secretes pro-inflammatory 
(i.e. C-reactive protein, leptin) and anti-inflammatory (i.e. adiponectin) adipokines. The pro-
inflammatory adipokines promote endothelial dysfunction, insulin resistance and, therefore, 
atherosclerosis (5). In contrast, adiponectin is inversely associated with insulin resistance and 
non-alcoholic fatty liver disease (NAFLD), protecting for metabolic syndrome (MetS) and T2DM 
(5,6). These MetS factors are supposed to be linked with increased cardiovascular risk in T2DM 
(7-9). VAT volume assessed by computed tomography (CT) was shown to be associated with 
subclinical atherosclerosis assessed by whole body magnetic resonance angiography (MRI) (10). 
Importantly, in non-obese populations, VAT volume appeared to be associated with 18F-fluoro-
2-deoxy-D-glucose positron emission tomography (FDG-PET) assessed arterial inflammation 
(11), suggesting that VAT creates a pro-inflammatory environment even in the absence of MetS 
and T2DM. FDG-PET assessed arterial inflammation is a marker of premature atherosclerosis 
(12) and predicts cardiovascular events independent of traditional risk factors in asymptomatic 
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adults (13).  MetS, including HOMA-IR as a proxy for insulin resistance, seems an important 
determinant of arterial inflammation (12), potentially linking visceral adiposity to enhanced 
arterial inflammation in diabetes. 
 We hypothesize that VAT volume is an important determinant in the pathogenesis of 
arterial inflammation in patients with T2DM, independent of the classical risk factors. Therefore, 
we studied the association of CT-assessed abdominal VAT and SAT volumes with FDG-PET 
assessed arterial inflammation in a homogenous obese population of T2DM patients without 
glucose lowering treatment and without a history of CVD. Furthermore, we assessed the 
association with sex, additional MetS components (hypertension, dyslipidaemia, and HbA1c), 
HOMA-IR as an index of insulin resistance, liver function tests and CT-assessed NAFLD as indices 
of NAFLD, the adipokine adiponectin, leptin, and CRP.   
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MATERIALS AND METHODS 
Study design 
This single centre, cross-sectional study included participants from a previously 
conducted study; the RELEASE trial (14,15). This study was performed in compliance with the 
principles of the Declaration of Helsinki. All patients gave written informed consent. The 




Eligibility criteria were described in detail previously (14). Briefly, potentially eligible 
early T2DM patients without glucose lowering drug treatment and aged between 30 and 70 
years were included. T2DM was defined according to the criteria formulated by the American 
Diabetes Association. Exclusion criteria were current glucose-lowering drug use, uncontrolled 
hypertension (SBP >160 mmHg or DBP > 100 mmHg), history of CVD defined as stable coronary 
artery disease or acute coronary syndrome, stroke or transient ischemic attack, or peripheral 
artery disease.  
 
Clinical and Laboratory Assessments 
The following clinical data were evaluated: age, sex, medical history, drug use, and 
cardiovascular history. Also, blood pressure, weight,  height and waist circumference (WC) were 
determined. BMI was calculated by dividing weight by height squared (kg/m2). All blood samples 
were obtained in the morning after at least 8 hours of overnight fasting, and plasma glucose, 
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insulin, HbA1c, lipid profile, alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
and gamma-glutamyl transferase (GGT) and CRP were measured using routine automated 
assays. Estimated Glomerular Filtration Rate (eGFR) was measured as marker of kidney function 
using CKD-EPI formula. Liver function tests ALT, AST, and GGT were measured as an indication of 
NAFLD. Total plasma adiponectin and leptin plasma levels were determined with an Enzyme 
Linked Immuno Sorbent Assay (ELISA) kit (Linco Research, St Charles, Mo, USA; EZHADP-61K and 
EZHL-80SK). Insulin resistance was estimated with the HOMA-IR: fasting insulin * fasting glucose 
/ 22.5) (16).  
 
FDG-PET/CT Imaging and arterial FDG uptake 
Patients fasted for a minimum of 6 hours, and blood glucose concentrations were ensured to be 
less than 11 mmol/L before 3 MBq FDG/kg body weight was administered intravenously. All 
FDG-PET/CT scans were performed approximately 60 minutes after FDG administration on a 
Siemens Biograph 64 slice PET/CT scanner (Siemens Medical Systems, Knoxville, Tn, USA) 
according to the European Association of Nuclear Medicine (EANM) procedure guidelines for 
FDG imaging (17). Low-dose CT was performed before the PET-emission for attenuation 
correction and anatomic mapping with 100 kV and 30 mAs. PET emission data were acquired 
from the skull to knee, three minutes per bed position.  
Arterial inflammation was quantified as the maximum standardized FDG uptake value 
(SUVmax) in the arteries as described earlier (14). In short, SUVmax was calculated by dividing 
radioactive concentration (kBq/mL) by (activity injected (kBq)/weight (g)). The SUVmax in arteries 
was measured by manually drawing three-dimensional Volumes of Interest (VOIs). VOIs were 
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separately drawn around the carotid arteries, ascending aorta and aortic arch, descending and 
abdominal aorta, and iliac and femoral arteries and adjusted for the pre-scan glucose value and 
background activity by the caval veins blood pool activity, yielding a mean arterial target-to-
background ratio (meanTBR).  
 
Adipose tissue volume analysis 
All measurements were performed using MATLAB software (version R2015b The 
MathWorks, Inc, Natick, MA, USA) as previously described (18). In order to analyse the entire 
abdomen, all slices from vertebral levels L1 to L5 were manually selected. Adipose tissue was 
initially segmented by thresholding the CT images between -174 and -24 Hounsfield Units (HU) 
(18). Adipose tissue volumes were determined using a semi-automated method (18). The 
abdominal muscular layer was used as a boundary to separate VAT from SAT, see Figure 1.  
 
CT-assessed NAFLD analyses 
 Fatty liver analyses were performed on CT as a proxy for NAFLD. These analyses were 
done with the method of Zeb. et al. (19), based on CT images.  In brief, ratio of liver-to-spleen 
HU was used to assess the severity of NAFLD. HU decreases in the development of NAFLD. Ratio 
was calculated as the mean of three regions of interest of mean HU value of the liver, divided by 
the mean HU of one region of interest of the spleen. HU < 1.0 was used to diagnose NAFLD. The 






Discrete variables are presented as numbers with percentages. Quantitative variables 
with a normal distribution are presented as mean ±SD and not normally distributed as median 
with interquartile range (IQR). All statistical analyses were performed with IBM Statistical 
Package for Social Sciences (SPSS) version 23. Independent t-test in normally distributed 
variables, a Mann-Whitney U test in not-normally distributed variables and a one-way ANOVA in 
categorical variables were used to compare groups. Univariate associations with VAT and SAT 
volumes were assessed and a possible relation between meanTBR and potential confounders was 
investigated with Spearman’s correlation coefficient (R).  
Multiple linear regressions were used to examine factors associated with the meanTBR 
and to assess whether VAT volume was associated with meanTBR independently of anticipated 
factors. Five models were constructed to sequentially evaluate the addition of MetS on the 
association of VAT volume with meanTBR (Model 1). Because of sex differences in adipose tissue 
distribution, the interaction of sex vs. VAT volume was tested and all models were corrected for 
sex as well as for the interaction term of VAT volume * sex. After including VAT volume, sex, and 
the interaction term (Model 2), components of MetS were added sequentially: HbA1c, or BMI, 
or triglycerides and HDLc, or SBP and DBP separately (Model 3), HOMA-IR and ALT (Model 4), 
HOMA-IR and CT-assessed NAFLD (Model 5), and adiponectin, leptin, and CRP (Model 6). P ˂ 








In total, 44 early T2DM patients participated in the study of which 27 males and 17 
females. Clinical characteristics are presented in Table 1.  
VAT volume was associated with BMI, waist circumference, eGFR, ALT, AST, GGT, HOMA-
IR, adiponectin, and leptin. Relation between VAT volume with HOMA-IR and adiponectin is 
shown in Figure 2. VAT and SAT volumes were not interrelated. No associations of VAT volume 
with MetS components (lipids, blood pressure, and HbA1c) or CRP were found, as shown in 
Table 2. Additionally, SAT volume did not correlate with liver function tests and CT-assessed 
NAFLD, neither with lipids, blood pressure, and HbA1c. However, SAT volume was associated 
with leptin levels (r=0.817, p<0.001).  
 
Association of VAT and SAT volume with arterial FDG uptake 
VAT volume (r=0.348, p=0.022) correlated significantly with meanTBR, see Figure 3. In 
contrast, SAT volume did not correlate significantly with meanTBR (r=0.045, p=0.773). meanTBR 
showed to be significantly associated with HbA1c (r=0.434, p=0.003) and systolic blood pressure 
(r=0.338, p=0.029) as shown in Table 2. 
The association between VAT volume and meanTBR was modified by sex (interaction VAT 
volume * sex p=0.026). Therefore, we included this interaction variable in the multiple linear 
regression models. Furthermore, adding MetS components BMI, SBP and DBP, and triglycerides 
and HDLc separately, did not alter the association between VAT volume and meanTBR (data not 
shown). All models showed that VAT volume remained significantly associated with meanTBR, as 
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shown in Table 3. While HbA1c was positively associated with the association between meanTBR 
and VAT volume, the models with HOMA-IR and NAFLD (ALT or CT-assessed NAFLD) or 







In this cross-sectional study we demonstrated that VAT volume, contrary to SAT volume, 
was associated with arterial FDG-PET as a marker of arterial inflammation in early T2DM. This 
association remained present even after adjustment for sex, HbA1c, insulin resistance (HOMA-
IR) and NAFLD (ALT and CT-assessed NAFLD), and levels of adipokines (adiponectin, leptin, and 
C-reactive protein). These findings confirm previous reports that VAT is linked to arterial 
inflammation, which is considered an early step in the atherosclerosis process. This process 
possibly results in premature atherosclerosis as observed in T2DM, even early in the course of 
the disease with only mild hyperglycaemia. We found a significant correlation of arterial 
inflammation with well-known components of the MetS. Sex did play an important role in this 
association. Therefore, we included interaction variable VAT volume * Sex. The correlation 
showed to be independent of sex. However, Also, the MetS factors did not influence the 
association of VAT with arterial inflammation in the current study, suggesting that other 
unknown factors may mediate the development of premature atherosclerosis.  
To the best of our knowledge, this is the first study in an early T2DM cohort to analyse 
the effect of adipose tissue volumes on arterial FDG uptake. We differentiated between VAT 
and SAT in relation to arterial FDG uptake and studied the effect of pathophysiological 
confounders potentially mediating the association between VAT and arterial inflammation. This 
study, therefore, improves and refines the understanding of the relation between adiposity and 
cardiovascular risk in T2DM, although the precise underlying mechanism of adiposity-enhanced 
arterial inflammation needs to be identified.   
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Arterial inflammation in relation with VAT volume was studied before (20,21). However, 
the study population differed from our study. While we studied a prospectively selected, well 
defined, homogeneous, high risk cohort with obesity and early T2DM with a median BMI of 
30.4, Hong et al. scanned healthy check-up subjects with a median BMI of 24.8. Figueroa et al. 
scanned patients who came for oncological evaluation with a median BMI of 26.4. Our study 
therefore expanded the results of these studies in the target population. Nevertheless, a 
positive association of waist circumference with carotid FDG uptake has been found in patients 
with MetS (12). In the study of Tahara et al., abdominal waist circumference was studied as a 
proxy for VAT. When in fact, this measure also includes SAT. Our results now show that VAT 
volume is indeed an independent factor associated with arterial inflammation, whereas SAT is 
not. Also, waist circumference in our study did not correlate with arterial inflammation. These 
results are in line with the concept that VAT is known to produce more pro-inflammatory 
adipokines compared to SAT (4).  Furthermore, VAT is associated with CVD risk factors (8,22) 
and future CVD events, even after adjustment for CVD risk factors and generalized adiposity 
(23,24). Our study not only confirms these studies, but also clarifies that these effects also occur 
at a very early disease stage.  
 Several studies investigated VAT in relation to proxies of subclinical atherosclerosis. A 
positive relation was found between VAT with ultrasound assessed common carotid intima-
media thickness (25,26) and coronary and abdominal aortic calcium (27). Different technical 
methods were used for measuring VAT, including ultrasonography (25), MRI (26), and CT (27). In 
contrast to these methods which visualize later (irreversible) stages, we used FDG-PET for 
measuring one of the earliest stages of atherosclerosis that can be assessed in vivo. This method 
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is intended to detect the most premature stages of atherosclerosis, when there are still no 
detectable structural changes. We previously demonstrated that ex vivo FDG-uptake in carotid 
plaques strongly correlates with macrophage plaque infiltration (28). Furthermore, FDG-PET 
assessed arterial inflammation is strongly associated with pulse wave velocity, which is 
considered a clinical proxy for endothelial dysfunction in early T2DM (14). Although arterial 
inflammation was measured with FDG-PET before in the carotid artery (12,20) and ascending 
aorta (21), our study extends these findings as we measured FDG-uptake in ten different artery 
segments within the individual patient thereby providing a more accurate estimation of the 
total body arterial inflammation. 
The underlying mechanism of VAT leading to atherosclerosis is incompletely understood. 
In a previous study, MetS was shown to be an important determinant of arterial inflammation 
(12). Remarkably, we did not find significant associations between VAT volume and MetS 
components lipids, systolic blood pressure and HbA1c. This could potentially be due to the use 
of statins, blood pressure lowering drugs and HbA1c levels. HbA1c in our study did not correlate 
with VAT. But HbA1c was relatively low in this treatment naive T2DM population. Importantly, a 
clear association with insulin resistance was indeed observed. Furthermore, VAT volume proved 
to be associated with two other biomarkers of VAT dysfunction, i.e. total plasma adiponectin, 
and liver function tests and CT-assessed NAFLD as proxies for NAFLD. In this study also we 
investigated the effect of several plausible pathophysiological confounders, which has not been 
studied before. Influence of insulin resistance, NAFLD, and adipokines on the association 
between arterial inflammation and VAT volume was not investigated before (12,20,21). 
Moreover, in previous studies, results were not corrected for sex, while sex is a key factor in 
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adipose tissue distribution (29).  Although we can only speculate, our result suggests that other 
factors play a role when VAT volume increases. Additional, unassessed cytokines, such as TNF-α, 
which are secreted by adipose tissue after macrophage recruitment, oxidative stress, or 
hormonal factors could play a role (30). The underlying mechanism of the influence of adipose 
tissue in the development of atherosclerosis still needs further investigation.  
Another factor that could possibly stimulate atherosclerosis in T2DM is leptin. Although 
leptin reduces appetite (31), obese individuals show resistance to leptin, which results in 
elevated levels failing to control appetite and therefore, weight gain (32). The exact effect of 
leptin in T2DM is unclear; it could be either a cause or effect of adipose tissue volume. In our 
study, we found a significant association between SAT volume and leptin levels. However, leptin 
did not influence the association between VAT volume and arterial inflammation.  
This study has some limitations. First, the relative small observational cohort limits the 
power in our study. Second, almost 55% of the patients already used a statin. Statins affect the 
arterial inflammation (33) and lipid levels. However, patients were only included if they had 
been on a stable dose of statins. So our main associations might be an underestimation of the 
true effect, at least in statin users. Third, we performed a low dose (ld) CT with lower 
resolutions compared to diagnostic CT scans. But, the quality of the ldCT scans was appropriate 
to differentiate adipose tissue from surrounding tissues and the radiation dose is much less 
compared to diagnostic CT scans. Furthermore, the value of HOMA-IR is not uniform and 
depends on many factors including demography, BMI, age and sex. HOMA-IR is a value for 
whole body insulin resistance whereas insulin resistance could vary substantially between 
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different organs and tissues. But, HOMA-IR is commonly used as a marker of insulin resistance 
and is the most accurate assessment of insulin resistance at this moment.  
In conclusion, CT-assessed VAT volume is associated with FDG-PET assessed arterial 
inflammation as marker of premature atherosclerosis in early T2DM. This association is 
independent of sex and traditional MetS risk factors in T2DM patients, including 
pathophysiologically relevant biomarkers for VAT dysfunction. More insight in this association 
may help to identify T2DM patients at particularly high risk of CVD, allowing early interventions.   
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Table 1: Characteristics of the total early type 2 diabetes mellitus population. 
  Total population  
(N = 44) 
Male (%) 27 (61%) 
Age (years) 63 (54-66) 
T2DM duration (years) 1 (0-3.8) 
BMI (kg/m2) 30.4 (27.5-35.8) 
Manually measured waist circumference (cm) 101 (94-108) 
Systolic blood pressure (mmHg) 137 (127-147) 
Estimated glomerular filtration rate (mL/min/1.73m2) 85 ± 14 
HbA1c (%) 6.3 ± 0.43 
HOMA-IR 5.1 (3.1-8.5) 
Total cholesterol (mmol/L) 4.8 ± 0.95 
HDL (mmol/L) 1.3 (1.1-1.5) 
LDL (mmol/L) 3.1 ± 1.0 
Triglycerides (mmol/L) 1.4 (0.91-2.0) 
Alanine transaminase (U/L) 26 (20-44) 
Aspartate transaminase (U/L) 26 (22-33) 
Gamma-glutamyl transferase (U/L) 34.5 (25.0-46.5) 
Computed tomography-assessed non-alcoholic fatty liver disease (%) 17 (39%) 
Glucose (mmol/l) 7.4 ± 0.97a 
Adiponectin (ng/ml) 7.9 (6.3-10.5) 
Leptin (ng/ml) 13.2 (6.4-25.6) 
C-reactive protein (mg/l) 1.2 (0.70-3.1) 
Visceral adipose tissue volume (cm3) 7.97 (6.55-10.58) 
Subcutaneous adipose tissue volume  (cm3) 8.86 (5.57-13.31) 









Table 2: Relation of VAT volume and meanTBR with T2DM associated risk factors.  




 Correlation coefficient r P-value Correlation coefficient r P-value 
BMI 0.47  0.001 0.30 0.051 
Waist circumference 0.64  <0.001 0.22 0.159 
Systolic blood pressure 0.90 0.569 0.34 0.029 
Estimated Glomerular Filtration Rate 0.37 0.013 0.25 0.109 
HbA1c 0.19 0.207 0.43 0.003 
HOMA-IR 0.37  0.015 0.10 0.506 
Total Cholesterol -0.11 0.476 0.10 0.526 
HDL -0.17 0.272 -0.21 0.171 
LDL -0.14 0.385 0.09 0.579 
Triglycerides 0.27 0.077 0.23 0.134 
Alanine transaminase 0.57  0.000 0.28 0.071 
Aspartate transaminase 0.42  0.005 0.53 0.098 
Gamma-glutamyl Transferase 0.33  0.028 0.17 0.263 
Adiponectin -0.39  0.008 0.085 0.584 
Leptin 0.08  0.631 -0.064 0.680 
C-reactive protein -0.023 0.880 -0.23 0.137 
Visceral adipose tissue volume   0.33 0.031 





Table 3: Arterial inflammation and VAT volume: multivariate linear regression models. 
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VAT volume 0.42 0.004 1.56 0.002 1.30 0.002 1.34 0.002 1.34 0.003 1.36 0.002 
Sex   1.21 0.011 0.97 0.015 1.06 0.014 1.00 0.023 1.08 0.007 
Visceral Adipose 













HbA1c     0.48 <0.001 0.47 <0.001 0.43 0.001 0.47 <0.001 
HOMA-IR       0.11 0.452 -
0.16 
0.417   
Alanine 
transaminase 
      -
0.04 
0.077     
CT-assessed 
NAFLD 
        -
0.17 
0.342   
Adiponectin           0.14 0.274 
Leptin           -
0.23 
0.229 










Figure 1: Analysis of abdominal adipose tissue using semi-automated method (18). Figure 1A 
shows the closed muscle layer separating visceral adipose tissue (VAT) and subcutaneous 
adipose tissue (SAT). Figure 1B shows differentiated adipose tissue VAT (purple colored) and 
SAT (green colored).   
 
 
Figure 2: Relation of visceral adipose tissue volume (cm3) with HOMA Insulin Resistance (A) and 















Figure 3: Relation of visceral adipose tissue (VAT) volume (cm3) with arterial FDG uptake 
(meanTBR). 
 
